The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs

Unconjugated anti-cancer IgG1 monoclonal antibodies (mAbs) activate antibody-dependent cellular cytotoxicity (ADCC) by natural killer (NK) cells and antibody-dependent cellular phagocytosis (ADCP) by macrophages, and these activities are thought to be important mechanisms of action for many of these...

Full description

Bibliographic Details
Main Authors:	Josée Golay, Ronald P. Taylor
Format:	Article
Language:	English
Published:	MDPI AG 2020-10-01
Series:	Antibodies
Subjects:	therapeutic monoclonal antibodies (mAbs) complement antibody dependent cellular cytotoxicity phagocytosis complement receptors
Online Access:	https://www.mdpi.com/2073-4468/9/4/58

Similar Items

How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca<sup>2+</sup>
by: Ronald P. Taylor, et al.
Published: (2020-09-01)

CD20 mAb-Mediated Complement Dependent Cytotoxicity of Tumor Cells is Enhanced by Blocking the Action of Factor I
by: Margaret A. Lindorfer, et al.
Published: (2013-11-01)

Fc Binding by FcγRIIa Is Essential for Cellular Activation by the Anti-FcγRIIa mAbs 8.26 and 8.2
by: Bruce D. Wines, et al.
Published: (2021-10-01)

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
by: Patricia Gogesch, et al.
Published: (2021-08-01)

IgG Fc engineering to modulate antibody effector functions
by: Xinhua Wang, et al.
Published: (2017-10-01)

Fc glycan sialylation of biotherapeutic monoclonal antibodies has limited impact on antibody‐dependent cellular cytotoxicity
by: Elaine Branstetter, et al.
Published: (2021-11-01)

Bispecific mAb<sup>2</sup> Antibodies Targeting CD59 Enhance the Complement-Dependent Cytotoxicity Mediated by Rituximab
by: Katharina Stadlbauer, et al.
Published: (2022-05-01)

A Dual-Approach Strategy to Optimize the Safety and Efficacy of Anti-Zika Virus Monoclonal Antibody Therapeutics
by: Haiyan Sun, et al.
Published: (2023-05-01)

Taking the Hinge off: An Approach to Effector-Less Monoclonal Antibodies
by: Jamie Valeich, et al.
Published: (2020-09-01)

Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods
by: Emily K. Makowski, et al.
Published: (2021-01-01)

Contribution of Fc-dependent cell-mediated activity of a vestigial esterase-targeting antibody against H5N6 virus infection
by: Zhiqiang Zheng, et al.
Published: (2020-01-01)

Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease
by: Esther C. W. de Boer, et al.
Published: (2020-12-01)

Complement Activation in the Treatment of B-Cell Malignancies
by: Clive S. Zent, et al.
Published: (2020-12-01)

Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections
by: Pardis Mokhtary, et al.
Published: (2022-08-01)

Preclinical Characterization of a Novel Monoclonal Antibody NEO-201 for the Treatment of Human Carcinomas
by: Massimo Fantini, et al.
Published: (2018-01-01)

Monoclonal antibodies effectively potentiate complement activation and phagocytosis of Staphylococcus epidermidis in neonatal human plasma
by: Lisanne de Vor, et al.
Published: (2022-07-01)

Influenza and Antibody-Dependent Cellular Cytotoxicity
by: Tarra A. Von Holle, et al.
Published: (2019-06-01)

Fc-Engineering for Modulated Effector Functions—Improving Antibodies for Cancer Treatment
by: Rena Liu, et al.
Published: (2020-11-01)

Plant-Produced Anti-Zika Virus Monoclonal Antibody Glycovariant Exhibits Abrogated Antibody-Dependent Enhancement of Infection
by: Ming Yang, et al.
Published: (2023-03-01)

A New Trial to Measure ABO Antibodies Using Complement-Dependent Cytotoxicity
by: Hee-Jeong Youk, et al.
Published: (2022-06-01)

Identification of the O-Glycan Epitope Targeted by the Anti-Human Carcinoma Monoclonal Antibody (mAb) NEO-201
by: Kwong Y. Tsang, et al.
Published: (2022-10-01)

An update to monoclonal antibody as therapeutic option against COVID-19
by: Paroma Deb, et al.
Published: (2021-04-01)

Development and Characterization of an Anti-Cancer Monoclonal Antibody for Treatment of Human Carcinomas
by: Kwong yok Tsang, et al.
Published: (2022-06-01)

Concentration Effects in the Interaction of Monoclonal Antibodies (mAbs) with their Immediate Environment Characterized by EPR Spectroscopy
by: Haleh H. Haeri, et al.
Published: (2019-07-01)

Antitumor activity of chLpMab‐2, a human–mouse chimeric cancer‐specific antihuman podoplanin antibody, via antibody‐dependent cellular cytotoxicity
by: Mika K. Kaneko, et al.
Published: (2017-04-01)

Complement Inhibition and COVID-19: The Story so Far
by: Fodil S, et al.
Published: (2021-07-01)

Development of rapid immuno-diagnostic test for the early detection of tuberculosis
by: Anil Kumar Gupta, et al.
Published: (2016-01-01)

Decoding the Human Immunoglobulin G-Glycan Repertoire Reveals a Spectrum of Fc-Receptor- and Complement-Mediated-Effector Activities
by: Gillian Dekkers, et al.
Published: (2017-08-01)

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
by: Gustavo A. Arias-Pinilla, et al.
Published: (2021-04-01)

Targeting cancer with antibody-drug conjugates: Promises and challenges
by: Alexis Q. Dean, et al.
Published: (2021-01-01)

Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies
by: Boris Grinshpun, et al.
Published: (2021-01-01)

Non-Genetically Improving the Natural Cytotoxicity of Natural Killer (NK) Cells
by: Martin Villalba, et al.
Published: (2020-01-01)

Animal immunization merges with innovative technologies: A new paradigm shift in antibody discovery
by: Ponraj Prabakaran, et al.
Published: (2021-01-01)

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model
by: Anna Gustafsson-Lutz, et al.
Published: (2017-04-01)

Therapeutic efficacy of a potent anti-Venezuelan equine encephalitis virus antibody is contingent on Fc effector function
by: Jennifer L. Schwedler, et al.
Published: (2024-12-01)

Development and validation of an LC-MS/MS method for simultaneous quantification of co-administered trastuzumab and pertuzumab
by: Sandor Schokker, et al.
Published: (2020-01-01)

Trends involving monoclonal antibody (mAb) research and commercialization: A scientometric analysis of IMS Lifecycle R&D Focus Database (1980–2016)
by: Yunfeng Lai, et al.
Published: (2018-04-01)

Ab locks for improving the selectivity and safety of antibody drugs
by: Wen-Wei Lin, et al.
Published: (2020-06-01)

Enhancing pharmacokinetic and pharmacodynamic properties of recombinant therapeutic proteins by manipulation of sialic acid content
by: Sean Chia, et al.
Published: (2023-07-01)

Phagocytosis: Our Current Understanding of a Universal Biological Process
by: Eileen Uribe-Querol, et al.
Published: (2020-06-01)